| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 04/28/2026 | ±2.3% | +1.8% | over-priced |
| 02/27/2026 | ±1.6% | +0.9% | over-priced |
| 10/27/2025 | ±1.8% | -0.1% | over-priced |
| 07/28/2025 | ±2.2% | -1.2% | over-priced |
| 04/28/2025 | ±2.9% | +1.1% | over-priced |
| 02/27/2025 | ±2.0% | +2.9% | under-priced |
| 10/30/2024 | ±1.4% | -1.2% | over-priced |
| 07/26/2024 | ±2.4% | +3.2% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $5.88 | $14.8B | $2.3B |
| Q4 FY2025 | — | $15.1B | $3.2B |
| Q3 FY2025 | $6.99 | $16.1B | $2.8B |
| Q2 FY2025 | $7.35 | $14.8B | $3.0B |
CB (CB) reports imminently, with the next report estimated for 10/26/2026. Across the last 8 reports, options priced an average ±2.0% earnings move while the stock actually moved 1.6% on average — the market has systematically over-priced CB's earnings risk. Fundamentals into the print: EPS up 78.7% year-over-year, revenue up 10.6%. QuantLogix's live 5-factor engine currently reads CB as a buy at 66/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →